GAA genepharm australasia limited

Neuren is significant undervalued ...Neuren Pharma (...

  1. 92 Posts.
    Neuren is significant undervalued ...
    Neuren Pharma ( NEU.AX)
    Marketcap: only 48 million A$
    Price: 0,34 A$

    Awesome Pipeline :

    Glypromate MCI in CABG US Phase 3 ongoing
    NNZ-2566 Severe TBI Phase 2a (deal with US Army)
    NNZ-2566 Mild/Mod TBI Phase 2
    Motiva Apathy Phase 2b

    Taylor Collison
    http://preset.sphilo.com/neuren/images/NEU%200708%20-%20Hamilton.pdf

    By the end 1Q CY08, we expect Neuren to be running four major
    efficacy trials; namely three Phase 2 trials for NNZ-2566 in
    mild/moderate and severe TBI and Motiva™ in post stroke abulia/
    depression coupled with the current Phase 3 trial for Glypromate® in
    CABG. All indications potentially provide Neuren with first to market,
    billion dollar opportunities. With a current market cap of $40.2m, Neuren
    remains a solid value proposition in the sector, where FDA INDs for mid
    to late stage clinical trials continues to remain a vexing proposition. We
    maintain our Speculative Buy recommendation and price target of $1.30,
    though expect to make changes to our valuation model once the
    acquisition has closed, which we expect during the current Q.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.